Edoxaban

證據等級: L5

預測適應症: 0 個

EDOXABAN (DB09075): Drug Repurposing Evaluation — Insufficient Data to Proceed

One-Sentence Summary

EDOXABAN is a small molecule drug (DrugBank: DB09075) that is currently not marketed in Taiwan, with no original indication data captured in this Evidence Pack. The TxGNN model returned no predicted indications for this candidate, making a substantive repurposing evaluation impossible at this stage. All critical data layers — mechanism of action, safety warnings, and model output — remain outstanding and must be resolved before this candidate can advance.

Quick Overview

Item	Content
Original Indication	Not available in current data
Predicted New Indication	None — TxGNN returned no predictions
TxGNN Prediction Score	N/A
Evidence Level	N/A
Taiwan Market Status	Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why No Evaluation Is Possible at This Stage

The Evidence Pack for EDOXABAN is missing three foundational data layers required before any repurposing analysis can proceed:

1. No TxGNN output. The predicted_indications array is empty. Without a scored candidate indication from the graph neural network, there is no repurposing hypothesis to evaluate. This is the central input for the entire pipeline.

2. No mechanism of action. The original_moa field is flagged as a data gap (severity: High). Without understanding how EDOXABAN exerts its pharmacological effect, it is impossible to assess whether any mechanistic bridge to a new indication is plausible.

3. No original indication confirmed. The original_indications array is empty. While EDOXABAN is publicly known to be a direct Factor Xa inhibitor used for anticoagulation (atrial fibrillation, DVT/PE), this information has not been validated from a regulatory source (TFDA package insert) in the current pipeline run and therefore cannot be used as a formal input.

Until these three gaps are closed, the evaluation framework cannot advance beyond data collection.

Safety Considerations

Please refer to the package insert for safety information.

Note: A TFDA package insert query was attempted on 2026-03-29 and returned a result (result_status: success), but the parsed content was not loaded into the safety fields of this Evidence Pack. The remediation step — parsing the downloaded PDF — appears incomplete.

Conclusion and Next Steps

Decision: Hold

Rationale: EDOXABAN has no TxGNN-predicted indications and no validated original indication or MOA data in the current Evidence Pack. There is no repurposing hypothesis to evaluate, assess mechanistically, or support with clinical evidence.

To proceed, all of the following must be resolved:

[Blocking] Run the TxGNN prediction pipeline for EDOXABAN (DB09075) to generate scored candidate indications
[Blocking] Parse the TFDA package insert PDF already retrieved (query log ID 4) to extract original indications, key warnings, and contraindications
[High] Query DrugBank API for mechanism of action (MOA) — DrugBank record confirmed to exist (query log ID 3, 1 result found)
[High] Re-run the Evidence Pack generation after the above inputs are available to produce a substantive L1–L5 evaluation

The DrugBank record and TFDA package insert are already confirmed to exist. Resolving this candidate does not require new data sourcing — it requires completing the parsing and pipeline steps already initiated.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.